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Abstract: 
Botanical dietary supplements are often targeted by the mainstream media and scientific/medical communities 
as being unscientific and unsafe relative to prescription pharmaceuticals and over-the counter drugs. However, 
the relative risk of botanical medicines is largely overestimated and causal relationships between botanical 
remedies and significant adverse reactions pale in comparison to the frequency and magnitude of those 
observed with normal use of FDA-approved pharmaceuticals. Historically, a greater premium has been placed 
on demonstrating the safety of health-related products as opposed to confirming therapeutic efficacy; in fact, the 
required standards for prescription drug efficacy were implemented in the U.S. more than 50 years after 
standards for purity and safety were firmly in place. An argument will be made that botanical manufacturers can 
support their place in the national health agenda and generate significant goodwill by voluntarily subjecting 
supplements to relatively simple and inexpensive preclinical studies, and even limited phase I clinical trials, 
employing the basic tenets of pharmacology and toxicology (i.e., dose-response relationships) to support the 
relative safety of specific products. Moreover, many of the unfortunate adverse events of drug-herb interactions 
over the last 10 years could have been prevented by relatively simple hepatic metabolism and drug transport 
studies that have become commonplace in even the smallest of academic laboratories, due in large part to the 
increased availability and lower cost of previously scarce and cumbersome biological reagents. Demonstrating 
the safety of semi-pharmaceutical formulations of herbal products now requires more than simple reliance on 
the historic folk record of safe use; real health risks and negative publicity can be successfully mitigated with a 
modest, prospective investment in basic preclinical toxicology testing. A model is presented for a non-profit 
research center that focuses on botanical quality and safety as a first step toward this goal. 
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Since the explosive growth of the international botanical medicine industry in the 1990s, the market for this 
class of dietary supplements has leveled off. In the US and Europe in particular, there have been three primary 
causes for this dampening of enthusiasm. First, is the appearance of reports of significant drug-herb interactions 
in high-profile journals, whereby previously unanticipated effects of botanical components on inducing hepatic 
drug metabolizing enzymes resulted in subtherapeutic blood levels of drugs used to treat HIV/AIDS and organ 
transplant rejection (Moore et al., 2000; Piscitelli et al., 2000; Ruschitzka et al., 2000). Second, a number of 
reports surfaced on the contamination and/or adulteration of botanical products with toxic heavy metals and 
current or obsolete prescription drugs (Ernst, 2002; Levine et al., 2002; Pittler and Ernst, 2003; Saper et al., 
2004). Third, and perhaps most damning to the industry, has been accumulation of clinical trials results 
indicating lack of therapeutic efficacy for some of the best-known, time-tested herbal remedies such as 
echinacea (Echinacea spp.)extracts for rhinoviral infections and saw palmetto (Serenoa repens) for benign 
prostatic hypertrophy (Turner et al., 2005; Bent et al., 2006). 
 
We propose that each of these broad classes of botanical misfortune might have been prevented by modest 
industry investment in analytical and quantitative chemistry studies, some basic preclinical toxicology studies, 
and basic Phase I human pharmacokinetic trials to correlate botanical dosing with target plasma concentrations 
of active constituents. In fact, one of the authors proposed such a coordinated approach at the 1997 Natural 
Products Expo East in Baltimore, MD, in his natural healing keynote address entitled, "Addressing the barriers 
to acceptance of herbs as medicines," to encourage the industry to use a scientific language and approach to 
cultivate botanical medicine use and acceptance among open-minded conventional healthcare practitioners 
(Kroll, 1997). 
 
For example, botanicals can be easily studied for their effect on inhibiting drug- metabolizing enzymes in vitro 
or by inducing these enzymes in cultured human hepatocytes (LeCluyse et al., 2000; Mathews et al., 2002). 
Similarly, botanical supplements can be easily monitored for contamination or adulteration with heavy metals, 
prescription drugs, pesticides and herbicides, and microbes or mycotoxins (Levine et al., 2002; Lau et al., 
2003). Lastly, clinical trial failures may be avoided by starting with an appropriately standardized and 
characterized botanical preparation and selection of doses capable of producing plasma concentrations of active 
principles consistent with biological efficacy surrogates observed in vitro (Kroll and Oberlies, 2003). Wolsko et 
al. (2005) recently addressed the problem of inadequate herbal supplement characterization in 81 published 
clinical trials. Only 12 (15%) of these trials reported performing tests to quantify botanical composition and 3 
(4%) of the trials provided data to compare actual with expected content of at least one chemical constituent. 
The costs associated with these botanical quality analyses would likely have been lower than the lost sales the 
industry has experienced as a result. In addition, botanical characterization and pilot pharmacokinetic studies 
should have been considered as a wise investment by funding agencies before approving the execution of 
multimillion dollar randomized, placebo- controlled clinical trials. 
 
As part of an independent, non-profit research institute, our research team is committed to the appropriate and 
safe access to effective botanical medicines by the general public. The methods, approaches, and philosophies 
are presented herein in the spirit of assisting our colleagues in the botanical industry of achieving this objective. 
The CFSAN-FDA International Conference on Quality and Safety Issues Related to Botanicals at Oxford, MS, 
USA, (2005) presented an opportunity to discuss, among a broad cross-section of stakeholders, the functional 
structure for an independent center dedicated to research on botanical quality and safety. 
 
THE NEED FOR A RESEARCH CENTER FOR BOTANICAL QUALITY AND SAFETY 
Botanical safety and herb-drug interactions represent two of the paramount challenges facing this country given 
the widespread use of herbal dietary supplements. Numerous statistics could be cited, and in particular, the 2004 
NCCAM report on U.S. complementary and alternative medicine usage rates makes clear that tens of millions 
of Americans use at least one botanical supplement every year (Barnes et al., 2004). The very existence of the 
NIH-ODS Botanical Research Centers program illustrates that the existing federal safety and efficacy standards 
are disproportionate relative to the widespread use of botanicals. If botanicals were regulated in a manner 
similar to prescription or OTC drugs, where the burden falls on the manufacturer to demonstrate product quality 
and safety, more than half of the studies proposed herein would be unnecessary. However, the current state of 
regulations places the burden for investigation of botanicals on appropriately trained researchers dedicated to 
this fascinating field, which requires the convergence of many scientific disciplines and funding by the NIH. 
 
In June 2004, the US National Institutes of Health (NIH) accepted applications for integrated Botanical 
Research Centers (BRCs). This request for applications (RFA-OD04-002) represented a renewal of a program 
supported in large part by the NIH National Center for Complementary and Alternative Medicine (NCCAM) 
and the NIH Office of Dietary Supplements (ODS), now with additional funds provided by the National 
Institute of Environmental Health Sciences (NIEHS). The program had previously funded six academic centers 
for the study of botanical agents in a variety of therapeutic areas, including women's health, cardiovascular 
disease, and diabetes. Since the original establishment of the program and the explosion of dietary supplement 
use in the U.S., a number of adverse reactions and drug-herb interactions have become increasingly reported in 
mainstream, peer-reviewed biomedical research journals. Moreover, several high-profile clinical efficacy trials 
of historically-useful botanical agents resulted in negative outcomes due, in part, to inadequate assurances of the 
quality, content, and bioavailability of the study agent employed. 
 
The RTI center for research on botanical quality and safety 
In order to address emerging safety issues, a team was assembled at Research Triangle Institute (RTI) to 
propose to NIH a unique approach: a center dedicated to the study of botanical quality and safety rather than 
study in a specific therapeutic area (Table 1). The RTI BRC would take advantage of a concentration of 
botanically relevant skills and capabilities that had been built at the Institute over the preceding decades. 
Moreover, the proposed center would also draw on botanical and clinical researchers that abound in the 
surrounding area known as Research Triangle Park. 
 
For example, RTI chemists are known for the discovery of the plant-derived antitumor drugs, taxol and 
camptothecin, isolated from the Pacific yew tree (Taxus brevifolia) and the Chinese tree of joy (Camptotheca 
acuminata), respectively (Oberlies and Kroll, 2004). Virtually all of the analytical and preparative techniques 
used for these agents can be applied easily to the characterization of complex botanical agent preparations. RTI 
researchers have long provided support to the National Toxicology Program of NIEHS for the provision of 
reference standards for botanical medicines, assessment of drug metabolizing enzyme interactions (hepatic 
enzyme induction and inhibition studies), and the bioavailability of botanical active principles in rodent models 
(Kim et al., 2001; Mathews et al., 2002; Kim et al., 2003; Levine et al., 2004; Oberlies et al., 2004). In-house 
expertise also includes sensitive analytical technologies for the detection of heavy metal contamination (using 
inductively-coupled plasma mass spectrometry), prescription drug adulteration, pesticide and herbicide 
contamination, and microbial and mycotoxin contamination (Akland et al., 2000; Hu et al., 2000; Menetrez and 
Foarde, 2002; Milstein et al., 2003; Graf et al., 2004; Levine et al., 2004; Menetrez and Foarde, 2004). 
 
Collaborative relationships exist with other hepatic biology experts such as Dr. Edward LeCluyse, then of the 
University of North Carolina (UNC). Moreover, the group has existing relationships with local and nationally-
recognized botanists such as Dr. Peter White, curator of the North Carolina Botanical Garden, and Trish Flaster, 
M.S., CEO of Botanical Liaisons of Boulder, CO for botanical identification, taxonomy, and the deposition and 
documentation of voucher specimens. 
 
Clinical experts in the area also agreed to provide support to the group, including UNC's director of their 
General Clinical Research Center and member of the NIH Drug- Induced Liver Injury Network (DILIN), Dr. 
Paul Watkins, and Phase I clinical trialists at Duke University Medical Center. With the exception of Ms. 
Flaster, all expertise required for execution of the Center's research resided within a 10 mile radius. 
 
Although the application was not selected for funding following the competitive evaluation process, NIH 
reviewers were highly enthusiastic about this interdisciplinary group of laboratories capable of assessing 
botanical quality and contaminants in noting, "each of these areas is a specialty, so assembling a competent 
group to perform these disparate tasks would be difficult in another setting." 
 
THE LIVER AS A SITE FOR BOTANICAL-DRUG INTERACTIONS AND TOXICITY 
As most botanical supplements are administered orally, the liver and, to a lesser extent, the intestinal mucosa 
both represent sites at which pharmacokinetic drug-herb interactions can occur. Conjugases, transporters and 
the monooxygenase cytochrome P450 (P450) are present in the intestine and liver, where they play a major role 
in presystemic metabolism. P450 is often the preeminent metabolic enzyme in those tissues, and the P450 forms 
CYP1A2, 2C9, 2C19, 2D6 and 3A4 together account for the metabolism of approximately 90% of all clinically-
prescribed drugs (Smith et al., 1998). Accordingly, package inserts included with prescription drugs now report 
data on the in vitro inhibition of human P450 enzymes as a means of predicting drug interactions mediated by 
competition for metabolism by the same enzyme. It is anticipated that, in the future, information on interactions 
with specific intestinal transporters will be included as well because of their marked impact on the 
bioavailability of the drugs which they transport. 
 
The P450 enzyme family is also of historical relevance in botanical medicine due to its role in the hepatotoxic 
effects of xenobiotics (Stedman, 2002). Hepatotoxicity is a leading cause of drug-related fatalities, due 
primarily to the fact that these phase I drug- metabolizing enzymes can bioactivate natural and synthetic 
compounds to chemically- reactive metabolites (Villeneuve and Pichette, 2004). Most of the herbs capable of 
this effect have been removed from the market, although comfrey (Symphytum officinale) supplements and teas, 
known sources of hepatotoxic pyrrolizidine alkaloids, continue to be sold (Kim et al., 2001; Oberlies et al., 
2004). Moreover, recent positive clinical trial results with pyrrolizidine alkaloid-free butterbur (Petasites 
hybridus) extract, Petadolex, in migraine prophylaxis (Lipton et al., 2004) suggests that scientists and clinicians 
should be vigilant in monitoring for hepatotoxic adverse events that may arise from ingestion of lower quality, 
copycat products that are likely to surface (Kalin, 2003). This issue is of such great importance to stakeholders 
that the 2003 gathering sponsored by the National Center for Natural Products Research and the Center for 
Food Safety and Applied Nutrition was entitled, "Hepatotoxicity Assessment for Botanical Dietary 
Supplements." The reader is referred to the meeting summary (Walker, 2005) authored by Dr. Larry Walker, 
director of the University of Mississippi National Center for Natural Products Research for a discussion of 
methods that might be employed to screen botanical supplements for predictable hepatotoxic reactions. 
 
Roughly 50 percent of drug-drug interactions have a pharmacokinetic basis in the liver (and/or intestine) and 
this has proven to be the case with drug-herb interactions as well. The biology of the cytochrome P450 family 
was at the heart of several, high-profile drug-herb interactions observed between St. John's wort (Hypericum 
perforatum) extracts and prescription drugs used in life-threatening situations such as HIV/AIDS or in post- 
organ transplant immunosuppression (Piscitelli et al., 2000; Ruschitzka et al., 2000). We propose that 
prospective analysis of the acute and chronic effects of St. John's wort extracts on the purified drug-
metabolizing enzymes and enzyme activity in cultured human hepatocytes might have prevented the negative 
press associated with these high profile mishaps. 
 
For example, a major advance in understanding CYP3A4 regulation was the discovery and cloning of the 
pregnane X receptor transcription factor (PXR) (Kliewer et al., 1998). This orphan nuclear 
receptor/transcription factor was shown to bind with high affinity several well-known CYP3A4 inducing agents, 
such as rifampicin, and activate transcription of the CYP3A4 gene via a specific PXR-response element (PRE). 
Subsequently, Kliewer's group demonstrated that hyperforin from St. John's wort was an even more effective 
PXR ligand than rifampicin (Moore et al., 2000). Hyperforin was therefore responsible for these CYP3A4-
mediated herb-drug interactions that began to surface in 1999 and 2000 whereby chronic St. John's wort use 
was associated with increased hepatic clearance and subtherapeutic drug levels of the HIV protease inhibitor, 
indinavir, and the immunosuppressive drug, cyclosporine. 
 
In another cancer-related study, St. John's wort was reported to enhance the clearance of irinotecan (CPT-11; 
Camptosar
®
), a semi-synthetic camptothecin used in advanced colorectal cancer (Mathijssen et al., 2002). 
Patients receiving St. John's wort with irinotecan experienced a 40% decrease in levels of the active metabolite, 
SN-38, thereby compromising the anticancer effect of the camptothecin. This effect persisted even when St. 
John's wort was discontinued for three weeks prior to the next course of chemotherapy. Induction of CYP3A4 
has been hypothesized as the mechanism by which St. John's wort modulates irinotecan clearance, indicating 
the potential for numerous interactions between herbal products and cytotoxic chemotherapeutic agents. 
CYP3A4 is known to metabolize a number of chemotherapy agents, including etoposide (VP-16) and vinca 
(Vinca rosea) alkaloids, and to play a role in the activation of ifosfamide to its alkylating species (Kivisto et al., 
1995). Therefore, long-term use of herbal products known to induce the activity of this enzyme, such as St. 
John's wort, might lead to increased clearance of numerous chemotherapeutic agents and possibly enhance the 
bioactivation and toxicity of ifosfamide. 
 
Conversely, acute exposure to herbal products has been shown to inhibit the activity of CYP3A4 (Budzinski et 
al., 2000; Obach, 2000; Gaudineau et al., 2004), representing the potential for amplified effects of several 
cytotoxic agents, such as etoposide or the Vinca alkaloids, or prevention of the CYP3A4-dependent activation 
of ifosfamide. Therefore, the timing and the context of herb use is of particular importance in defming the 
potential for drug-herb interactions. 
 
ACTUAL COSTS OF ASSESSING DRUG-METABOLIZING ENZYME EFFECTS OF BOTANICALS 
A major perceived barrier to prospective analysis of botanical supplement effects on drug-metabolizing 
enzymes is the cost of these studies. To address this perception, we solicited pricing information from the 
company of one of our former academic collaborators for these analyses. A complete panel of IC50 and K, 
inhibition studies for eleven P450 isoforms, monoamine oxidases A and B, aldehyde dehydrogenases, xanthine 
oxidase, and the UDP-glucuronyltransferase would cost approximately $6,000 per sample. Induction studies for 
the same enzymes (using enzyme activity or immunoblotting endpoints) in human hepatocytes would cost 
between $13,000 and $40,000, depending on the degree of complexity of studies required. If any inhibitory or 
inducing interactions are observed, historical or prospective pharmacokinetic studies could indicate the degree 
of likelihood that such an interaction might be expected in consumers taking prescription drugs concomitantly. 
Therefore, a botanical manufacturer could be rule out one major cause of drug-herb interactions for less than 
$50,000 per supplement. While these studies are not required by the U.S. Food and Drug Administration, the 
marketing advantage of a product that has been tested for these effects is obvious. Moreover, movement by the 
industry towards this type of testing would be likely to generate significant goodwill among consumers and 
health-care providers. 
 
Obviously, the most appropriate setting in which to assess metabolism-based botanical drug-herb interactions is 
in human subjects. One approach has been the use of model substrates for specific P450 isoforms (Gurley et al., 
2002; Gurley et al., 2006) as outlined by the excellent work of Dr. Bill Gurley at the University of Arkansas for 
Medical Sciences. For this reason, the proposed RTI BRC collaborates with clinical pharmacology colleagues at 
the University of North Carolina (Dr. Mary Paine) and one of the co-authors (H.S.S.) with others at Duke 
University Medical Center. These collaborations are essential to extrapolating in vitro studies to the actual 
setting of the consumer and patient, as well as to establish a framework for determining whether in vitro 
interactions observed are relevant given the in vivo plasma levels of botanically- derived active principles. 
 
AVOIDING PHARMACODYNAMIC BOTANICAL-DRUG INTERACTIONS 
Much of this discussion has focused on drug-herb interactions based on a botanical constituent inducing or 
inhibiting the metabolism of a drug, thereby reducing or increasing, respectively, the blood levels of a given 
drug. Depending on the direction of the change, the net effect of the interaction could be increased drug toxicity 
(especially for low-therapeutic index drugs such as cancer chemotherapeutics) or subtherapeutic blood levels of 
the drug, such that the patient is essentially undermedicated. 
 
Pharmacodynamic interactions are the result of one agent antagonizing the effect of another at the level of the 
cellular drug target. For example, our group is involved with two projects at the integrative oncology program 
for children's cancer at Columbia University led by Kara Kelly, M.D. and Elena Ladas, M.S., R.D. The projects 
include a clinical trial of a milk thistle (Silybum marianum) extract in prevention of liver toxicity of 
methotrexate chemotherapy in pediatric cancer patients, while the second is a clinical trial of glutamine 
supplementation to prevent peripheral neuropathy of vincristine chemotherapy. In both cases, it is essential to 
assure that side effect mitigation by supplement does not compromise desired anticancer activity of drug 
regimen. Using in vitro cancer cell survival experiments, we have confirmed that glutamine supplementation to 
concentrations expected in patients is without effect on the antileukemic activity of vincristine, L-asparaginase, 
or methotrexate chemotherapy. Similarly, milk thistle extracts have no effect on L-asparaginase or methotrexate 
efficacy. 
 
Hence, in no case were the supplements expected to interfere with the desired therapeutic effect of the 
antileukemic drug regimen. In fact, a surprising and useful observation arose from these studies, in that milk 
thistle extracts may synergize with vincristine in killing leukemia cells (Nakanishi et al., manuscript in 
preparation). Therefore, studying potentially negative drug-herb interactions also has the potential for revealing 
novel combinations that may enhance drug efficacy. Obviously, our group is currently pursuing funding sources 
to further investigate this potential synergy of milk thistle and vincristine in an appropriate model of human 
childhood leukemias. 
 
THE CASE OF CASE REPORTS 
Most botanical adverse reactions and drug-herb interactions first become apparent through publication of case 
reports. In particular, poison control centers have become important sentinels of adverse reactions and 
interactions (Dennehy et al., 2005). However, case reports are anecdotes and do not establish causality between 
a given botanical agent and the adverse reaction reported (Clouatre, 2004). The value of case reports is as 
hypothesis-generators. 
 
For example, we reported in 1998 on a case where use of an undefined St. John's wort extract by an asthmatic 
patient resulted in dramatically increased clearance of the oral bronchodilator, theophylline (Nebel et al., 1999). 
This association was supported by cell culture findings that hypericin in St. John's wort was capable of inducing 
activity via a major gene transcription element for CYP1A2. While work was ongoing to determine the 
causality of the interaction, we published a review article in the Journal of Herbal Pharmacotherapy (Kroll, 
2001) that bears quoting to emphasize the need for objectivity in evaluating the safety of herbal products: 
 
A less obvious area of negative bias is the publication of case reports. While valuable as flags for potential 
adverse effects and starting points for further studies, case reports on side effects due allegedly to herbal 
products have been used to indict the entire herbal medicine industry. Interestingly, we in conventional 
medicine urge our patients not to rely on anecdotal reports of efficacy of herbal products due to lack of 
blinding, placebo effects, and lack of consideration of the natural course of the disease. However, case reports 
(even the one published by this author on the theophylline-St. John's wort interaction) should also be viewed as 
anecdotal until substantiated further. (Kroll, 2001) 
 
Since our case report, two clinical studies have been published to follow-up on this finding. Gurley et al. (2002) 
used paraxanthine/caffeine phenotypic ratios to assess CYP1A2 activity in normal human volunteers before and 
after being given a St. John's wort supplement standardized to 0.3% hypericin, three times daily, for 28 days. 
The overall trend revealed a statistically-significant increase in CYP1A2 activity. However, six of the twelve 
individuals experienced no change in activity while the other six each experienced increases greater than the 
mean increase. A second study performed in twelve healthy males in Japan measured theophylline and its 
metabolites in plasma and urine after 14 days of St. John's wort extract at the same dose (Morimoto et al., 
2004). No significant changes were observed in any parameter. The conclusion that can be drawn is that St. 
John's wort may increase CYP1A2 activity in a subset of patients, but this increase is likely to be less dramatic 
than with the most intensively studied induction of CYP3A4. A factor that may account for the interindividual 
differences in the study of Gurley et al. and in our case report is that smoking produces polyaromatic 
hydrocarbons that might act in concert with hypericin in St. John's wort to increase CYP1A2 activity. Indeed, 
the patient in the case report was a cigarette smoker. 
 
What Should Happen Ideally After Botanical Adverse Reaction/Drug Interaction Case Reports Appear? 
As the case above illustrates, a rush to judgment is inappropriate until further studies are executed. The case 
report fueled discussions on the likelihood of causality between St. John's wort constituents and CYP1A2 
induction leading up to the generation of testable hypotheses in human volunteers in two countries. Ideally, test 
compound and representative extracts should be evaluated in progressively more relevant systems, from 
hepatocytes to whole animals to human studies. Potentially offending compounds from the botanical in question 
should also be tested for their bioavailability in progressively more relevant systems (Caco-2 permeability > 
rodent models > human studies) and mechanistic studies should follow (Clouatre, 2004; Zou et al., 2004). 
Wherever possible in vivo studies should proceed at physiologically relevant dosing, recognizing allometric 
scaling issues between rodents and humans (where 1 mg/kg in humans = 7 mg/kg in rats = 12 mg/kg mice). 
 
Most important is that botanical studies in human volunteers be expanded to include measurements of plasma 
concentrations of the purported pharmacologically- or toxicologically-relevant compound to determine whether 
the concentrations of compounds that elicit cell culture effects can even be achieved in an intact biological 
system or human volunteer. This point is important in interpreting safety issues of a botanical compound, since 
any number of effects can be observed in vitro that bear no relevance to plasma or tissue concentrations 
achieved in vivo. We have previously urged this point in efficacy trials, so that reports of negative outcomes 
could be correlated with whether botanical constituents achieved expected effective concentrations in 
volunteers. Similarly, botanical manufacturers may wish to have these data to defend against criticism of their 
products (i.e., a negative effect in vitro would be of no relevance if plasma levels of the offending compound 
are 1000-fold lower when the botanical is taken at a recommended dose). 
 
THE ROLE OF MEDIA TRAINING IN THE CAREER DEVELOPMENT OF BOTANICAL 
RESEARCHERS 
As a result of the intense public interest in botanical medicinal products, positive and negative research results 
are often the topic of mainstream press coverage. Barry Glassner's book, The Culture of Fear: Why Americans 
Are Afraid of the Wrong Things (Glassner, 1999), illustrates the interest of the press in seizing upon stories that 
have a sensationalistic aspect independent of their actual relative risk to human health. Therefore, the 
experience of the authors is that a botanical researcher is more likely to be contacted by the press than a 
research in another area whose work may have less immediate impact on human health. Therefore, it is 
important to provide some level of media training at all levels of career development in botanical research, not 
only to protect one's research message but also as an educational opportunity for the general public. 
 
We are fortunate to reside in a geographical area with a density of accomplished media figures dedicated to 
education of the public and have tapped these experts to provide media workshops to our trainees. Joe and Terry 
Graedon of National Public Radio's The People's Pharmacy have agreed to provide a workshop on radio 
interviewing. A television news workshop would be given by Tom Linden, MD, director of the University of 
North Carolina graduate program in medical journalism, and Helen Chickering, a reporter and producer for the 
national NBC News Channel portal. Interactions with the print news media would be covered by Tracey 
Koepke of the Duke University Medical Center News Office, along with others. Finally, like other institutions, 
our own office of public relations and corporate communications offers individualized press training. 
 
Appropriate training of scientists in interacting with the press can help to refine the message delivered to the 
public and increase the probability that an accurate representation of one's research results is disseminated. 
 
CONCLUSIONS 
A plan has been proposed to create an independent, non-profit, national center for research on botanical 
quality and safety to prevent the cases of misfortune that have plagued the integration of botanical medicine in 
the US healthcare system. Dietary supplement manufacturers enjoy a modest level of scrutiny by the US Food 
and Drug Administration, but a case has been made that voluntary adoption of basic preclinical and clinical 
evaluation of herbal products for quality and safety could have prevented the major adverse reactions, drug-herb 
interactions, and cases of product adulteration and contamination that have brought negative publicity to the 
industry. Voluntary adoption of suggested guidelines would also serve many intangible goals by increasing 
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